Nuvalent Tender Offer Closes with 91.3% of Shares Tendered; Merger Completion Imminent
NUVL sits 74% above its 52-week low of $71.13.
Summary
GSK's tender offer for Nuvalent expired with 91.3% of shares tendered, satisfying all conditions. The merger will close imminently, and Nuvalent shares will be delisted.
Key Events · M&A and Partnerships · NUVL
-
Tender Offer Expires with 91.3% Tendered
At the July 14, 2026 expiration, 72,518,967 shares—representing 91.3% of the outstanding total—were validly tendered, exceeding the minimum tender condition.
-
Merger to Close Without Stockholder Vote
With sufficient shares now in hand, the purchaser can complete the merger under Section 251(h) of the DGCL, removing the need for a stockholder meeting.
-
Delisting and Deregistration Imminent
Once the merger closes, Nuvalent shares will be delisted from Nasdaq and deregistered under the Exchange Act.
-
All-Cash Consideration of $124 Per Share
Each remaining share will be converted into the right to receive $124.00 in cash, consistent with the original offer price.
Analysis · NUVL · Life Sciences
GSK's $124 per share all-cash tender offer for Nuvalent expired on July 14, 2026, drawing 91.3% of outstanding shares—comfortably clearing the minimum condition. The purchaser has irrevocably accepted the tendered shares and will complete the acquisition via a short-form merger under Delaware law, bypassing a stockholder vote. Closing is expected promptly, after which Nuvalent shares will be delisted from Nasdaq and deregistered. This final step in the $10.6 billion acquisition delivers a substantial premium to shareholders near the 52-week high.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.6% of the 409 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NUVL was trading at $123.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $71.13 to $123.99. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.